The norepinephrine transporter (SLC6A2, NET) variant rs2242446/T-182C shows potential as a biomarker to predict the possibility of remission with venlafaxine in older adults with major depression, a recent study has found.
Performance of moderate-intensity exercise lasting at least 15 minutes, three times a week, potentially lowers the risk of depressive symptoms in older adults, a study has found. Furthermore, increasing exercise frequency to more than five times per week will benefit this population both physically and psychologically.
Female gamers with internet gaming disorder (IGD) have higher prevalence of sleep problems, which is associated with increased psychological distress and reduced life satisfaction, reports a new study.
Once-daily valbenazine is effective, safe and tolerable in the treatment of tardive dyskinesia in patients with underlying schizophrenia, schizoaffective disorder or mood disorder, according to the results of a phase III trial.
Low-dose naltrexone, in combination with single-day buprenorphine dosing and adjunctive nonopioid medications, has been found to be safe, effective and tolerable for initiating adults with opioid dependence to extended release (XR)-naltrexone, according to a recent study.